Competition & Peer Data API & CSV Delivery

Aridis Pharmaceuticals Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Aridis Pharmaceuticals Inc (ARDS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2023
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
4.51 %
Q4 2023
Net Margin
-19.90 %
Q4 2023

Key Findings: Aridis Pharmaceuticals Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 22M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is decelerating (-92.5% annualized vs trailing 12 months).
  • Peer revenue share: Aridis Pharmaceuticals Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

ARDS Sales vs. its Competitors, Q4 2023

Aridis Pharmaceuticals Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/ARDS/competitors
https://api.csimarket.com/api/v1/companies/ARDS/relationships
https://api.csimarket.com/api/v1/companies/ARDS/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 4.5% for Aridis Pharmaceuticals Inc. Aridis Pharmaceuticals Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.

Aridis Pharmaceuticals Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Aridis Pharmaceuticals Inc No Yes Yes No
Similar Growth & Profitability (8) 37.50 % (3 of 8) 100.00 % (8 of 8) 100.00 % (8 of 8) 33.30 % (2 of 6)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q4 2023

100%market share
  • Aridis Pharmaceuticals Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Aridis Pharmaceuticals Inc and its 0 tracked competitors.

See Aridis Pharmaceuticals Inc's full market share breakdown »

ARDS Stock Performance relative to its Competitors

ARDS Competitors (weighted) Percent change over the selected range

ARDS Stock Performance relative to Similar Growth & Profitability Competitors

ARDS Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range